Skip to main content
. 2015 Dec 28;7(4):4326–4343. doi: 10.18632/oncotarget.6775

Figure 6. SLMP53-1 sensitizes HCT116p53+/+ and MDA-MB-231 cells to the effects of etoposide and doxorubicin.

Figure 6

(A–C) Effects of combined treatment with 4 μM SLMP53-1 (or DMSO only) and increasing concentrations of doxorubicin (Doxo) or etoposide (Etop) on tumor cell growth, after 48 h; data are mean ± SEM (n = 4); the percentage of cell growth achieved with SLMP53-1 only was (A) 90.3% in HCT116p53+/+, (B) 99.8% in HCT116p53−/− and (C) 90.5% in MDA-MB-231 cells. (D) Effects of combined treatment with 4 μM SLMP53-1 (or DMSO only) and 0.19 μM doxorubicin or 0.38 μM etoposide on apoptosis after 48 h in MDA-MB-231 cells. The percentage of apoptotic cells obtained with SLMP53-1 only was 0.2%; data are mean ± SEM (n = 3). In A, C and D, the Q values are represented; dotted line represents Q = 1.15.